Cargando…
Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients
BACKGROUND: Evidence on safety and effectiveness of omalizumab for treatment of chronic urticaria in pediatric patients is scarce and limited to case reports. In particular, drug survival of omalizumab has not yet been investigated, which is a key element in the evaluation of its clinical performanc...
Autores principales: | Dekkers, Coco, Alizadeh Aghdam, Mehran, de Graaf, Marlies, Knulst, André C., Meijer, Yolanda, van den Reek, Juul M. P.A., Stadermann, Marike B., Röckmann, Heike |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248194/ https://www.ncbi.nlm.nih.gov/pubmed/33305439 http://dx.doi.org/10.1111/pai.13426 |
Ejemplares similares
-
Response of FcεRI‐bearing leucocytes to omalizumab in chronic spontaneous urticaria
por: Alizadeh Aghdam, Mehran, et al.
Publicado: (2020) -
Systemic and local evidence for complement involvement in chronic spontaneous urticaria
por: Alizadeh Aghdam, Mehran, et al.
Publicado: (2021) -
Recombinant human C1 esterase inhibitor as prophylactic treatment in idiopathic non‐histaminergic angioedema
por: Alizadeh Aghdam, Mehran, et al.
Publicado: (2022) -
Omalizumab for chronic urticaria in Latin America
por: Wilches, Paul, et al.
Publicado: (2016) -
Urticaria and angioedema as possible reactions of omalizumab
por: Ozbagcivan, Ozlem, et al.
Publicado: (2018)